The FDA’s Project Optimus aims to revolutionise dose optimisation in early-phase oncology drug development, focusing on selecting doses that minimise toxicity while maximising efficacy and tolerability.
This is a significant undertaking that requires drug developers to adopt a collaborative and proactive approach.
Partnering with a full-service, experienced CRO can help with implementing the key practical steps for success, improving cancer patients’ outcomes and quality of life.
Learn more in our latest blog and discover how we can support your Project Optimus journey.